Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: An uncontrolled experimental study with 24 weeks of follow-up

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1449-1454

  Haest, K ^a   Kumar, A ^a   Van calster, B ^a   Leunen, K ^a   Smeets, A ^a   Amant, F ^a   Berteloot, P ^a   Wildiers, H ^a   Paridaens, R ^a   Van limbergen, E ^a   Weltens, C ^a   Janssen, H ^a   Peeters, S ^a   Menten, J ^a   Vergote, I ^a   Morlion, B ^a   Verhaeghe, J ^a   Christiaens, M R ^a   Neven, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Hot flashes; Sleep disturbances; Stellate ganglion block

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; HOARSENESS; HORNER SYNDROME; HOT FLUSH; HUMAN; PILOT STUDY; PITTSBURGH SLEEP QUALITY INDEX; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; SLEEP DISORDER; STELLATE GANGLION BLOCK;

EID: 84861719015     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr478     Document Type: Article

References (41)

1. Canney PA, Hatton MQ. The Prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol (R Coll Radiol) 1994; 6: 297-299.
2. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995; 13: 2737-2744.
3. Pandya KJ, Raubertas RF, Flynn PJ et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132: 788-793.
4. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610-1620.
5. Nelson HD. Postmenopausal estrogen for treatment of hot flashes: clinical applications. JAMA 2004; 291: 1621-1625.
6. MacGregor CA, Canney PA, Patterson G et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005; 41: 708-714.
7. Mom CH, Buijs C, Willemse PH et al. Hot flushes in breast cancer patients. Crit Rev Oncol Hematol 2006; 57: 63-77.
8. Barron TI, Connolly R, Bennett K et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-839.
9. Hickey M, Emery LI, Gregson J et al. The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. Menopause 2010; 17: 727-733.
10. Morales L, Neven P, Timmerman D et al. Acute effects of tamoxifen and third generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004; 15: 753-760.
11. MacDonald PC, Edman CD, Hemsell DI et al. Effect of obesity on conversion of androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448-455.
12. Savage M, Brengelmann G. Control of skin blood flow in the neutral zone of human body temperature regulation. J Appl Physiol 1996; 80: 1249-1257.
13. Freedmann RR, Dinsay R. Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. Fertil Steril 2000; 74: 20-23.
14. Freedman RR. Hot flashes: behavioural treatments, mechanisms, and relation to sleep. Am J Med 2005; 118 (Suppl 12B): 124-130.
15. Sievert LL, Obermeyer CM, Price K. Determinants of hot flashes and night sweats. Ann Hum Biol 2006; 33: 4-16.
16. Casper RF, Yen SS. Neuroendocrinology of menopausal flashes: an hypothesis of flash mechanism. Clin Endocrinol (Oxf) 1985; 22: 293-312.
17. Tataryn IV, Meldrum DR, Lu KH et al. LH, FSH and skin temperature during the menopausal hot flash. J Clin Endocrinol Metab 1979; 49: 152-154.
18. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998; 70: 332-337.
19. Elias M. Cervical sympathetic and stellate ganglion blocks. Pain Physician 2000; 3: 294-304.
20. Lipov E, Mipov S, Start JT. Stellate ganglion blockade provides relief from menopausal hot flashes: a case report series. J Womens Health (Larchmt) 2005; 14: 737-741.
21. Lipov EG, Joshi JR, Sanders S et al. Effects of stellage-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008; 9: 523-532.
22. Lipov EG, Joshi JR, Xie H et al. Updated findings on the effects of stellateganglion block on hot flashes and night awakenings. Lancet Oncol 2008; 9: 819-820.
23. Pachman DR, Barton D, Carns PE et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer 2011; 19: 941-947.
24. Kontos M, Agbaje OF, Rymer J et al. What can be done about hot flashes after treatment for breast cancer? Climacteric 2010; 13: 4-21.
25. Sloan JA, Loprinzi CL, Novotny PJ et al. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001; 19: 4280-4290.
26. Finck G, Barton DL, Loprinzi CL et al. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998; 16: 327-333.
27. Lipov EG, Joshia JR, Sandersa S et al. A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Med Hypotheses 2009; 72: 657-661.
28. Kaur G, Janik J, Isaacson LG, Callahan P. Estrogen regulation of neurotrophin expression in sympathetic neurons and vascular targets. Brain Res 2007; 1139: 6-14.
29. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356: 2059-2063.
30. Stearns V, Isaacs C, Rowland J et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17-22.
31. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578-1583.
32. Barton DL, LaVasseur BI, Sloan JA et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28: 3278-3283.
33. Pandya KJ, Morrow GR, Roscoe JA et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 818-824.
34. Loprinzi CL, Qin R, Balcueva EP et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes N07C1. J Clin Oncol 2010; 28: 641-647.
35. Bordeleau L, Pritchard KI, Loprinzi CL et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010; 28: 5147-5152.
36. Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347-352.
37. Goodwin JW, Green SJ, Moinpour CM et al. Phase III randomized placebocontrolled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 2008; 26: 1650-1656.
38. Loibl S, Lintermans A, Dieudonné AS et al. Management of menopausal symptoms in breast cancer patients. Maturitas 2011; 68: 148-154.
39. Kim KH, Kang KW, Kim DI et al. Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women-a multicenter randomized clinical trial. Menopause 2010; 17: 269-280.
40. Jones JM, Loprinzi CL, Qin R et al. Hot flash placebo responses: related to baseline hot flash frequency? J Clin Oncol 2009; 27: 15S (Abstr 9628).
41. Martin DC, Willis ML, Mullinax LA et al. Pulsed radiofrequency application in the treatment of chronic pain. Pain Pract 2007; 7: 31-35.